



非何杰金氏淋巴瘤診療指引

淋巴瘤多專科團隊

2010年01月制訂

2011年10月修訂

2012年09月修訂

2013年01月修訂

2013年09月修訂

2014年12月修訂

2015年04月修訂



參考資料：

Non-Hodgkin' s Lymphomas NCCN Guidelines V1.2014

全民健康保險藥品給付規定 行政院衛生署一百零三年版

WORKUP


Essential:


- **Physical exam:** attention to node-bearing areas, including Waldeyer's ring, and to size of liver and spleen
- Performance status
- B symptoms
- CBC, differential, platelets
- LDH
- Beta-2-microglobulin (Optional)
- Comprehensive metabolic panel
- Hepatitis B testing
- Imaging: chest/abdominal/pelvic CT
- Bone marrow biopsy+aspirate
(Or select the whole body PET-CT)
- Pregnancy testing in women of child-bearing age (if C/T planned)


USEFUL IN SELECTED CASES:

- MUGA scan/echo if anthracycline or anthracenedione-based regimen is indicated
- Neck CT
- PET-CT scan (Optional)
- Uric acid
- Discussion of fertility issues and sperm banking
- SPEP and/or quantitative immunoglobulin levels
- Hepatitis C testing


→ Clinical Stage I, II, III, IV







HISTOLOGIC TRANSFORMATION TO DIFFUSE LARGE B-CELL LYMPHOMA



GELF CRITERIA


- Involvement of 3 nodal sites, each with a diameter of ≥ 3 cm
- Any nodal or extranodal tumor mass with a diameter of ≥ 7 cm
- B symptoms
- Splenomegaly
- Pleural effusions or peritoneal ascites
- Cytopenias (leukocytes $< 1.0 \times 10^9/L$ and/or platelets $< 100 \times 10^9/L$)
- Leukemia ($> 5.0 \times 10^9/L$ malignant cells)

FLIPI-1 CRITERIA

Age	60 y
Ann Arbor stage	III-IV
Hemoglobin level	< 12 g/dL
Serum LDH level	$> ULN$ (upper limit of normal)
Number of nodal sites	≥ 5

Risk group according to FLIPI chart

Low	Number of factors
Intermediate	0-1
High	2
	≥ 3



SUGGESTED TREATMENT REGIMENS
(in alphabetical order)

◆ **R-CVP**

Rituximab	375mg/m ² IV on day 1
Cyclophosphamide	400 mg/m ² IV on day 1-5 (or 800 mg/m ² IV on day 1-)
Vincristine	1.4 mg/m ² IV on day (maximum 2mg)
Prednisone	60 mg/m ² PO on day 1-5

Cycle every 21 days for 6-8 cycles

◆ **R-CHOP**

Rituximab	375mg/m ² IV on day 1
Cyclophosphamide	750 mg/m ² IV on day 1
Doxorubicin	50 mg/m ² IV on day 1
Vincristine	1.4 mg/m ² IV on day 1 (maximum 2mg)
Prednisone	60 mg/m ² PO on day 1-5

Cycle every 21 days for 6-8 cycles

◆ **R-mini CHOP**

Rituximab	375mg/m ² IV on day 1
Cyclophosphamide	400 mg/m ² IV on day 1
Doxorubicin	25 mg/m ² IV on day 1
Vincristine	1 mg IV on day 1
Prednisone	40 mg/m ² PO on day 1-5

Cycle every 21 days for 6-8 cycles



SUGGESTED TREATMENT REGIMENS

First-line therapy

Bendamustine + rituximab

Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract. Blood 2009;114:Abstract 405.

Cyclophosphamide

Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 2003;21:5-15.

CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + rituximab

Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular

remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:4711-4716.

Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab

added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-3732

CVP (cyclophosphamide, vincristine, prednisone) + rituximab

Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared

with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579- 4586.

FND (fludarabine, mitoxantrone, dexamethasone) + rituximab

McLaughlin P, Hagemeister FB, Rodriguez MA, et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 2000;27:37-41.

References

Rituximab

Hainsworth JD, Litchy S, Burris HA, III, et al. Rituximab as first-line and maintenance therapy for patients with indolent Non-Hodgkin's lymphoma. J Clin Oncol 2002;20:4261-4267.

Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 2001;97:101-106.

Radioimmunotherapy

Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441-449. Kaminski MS, Tuck M, Estes J, et al. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: Median 10 year follow-up results. Blood 2009;114:3759.

First-line consolidation or extended dosing

Chemotherapy followed by radioimmunotherapy

Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143-4149.

Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with Yttrium-90-Ibritumomab Tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-5164.

Hagenbeek A, Radford J, Van Hoof A, et al. 90Y-Ibritumomab tiuxetan (Zevalin®) consolidation of first remission in advanced-stage follicular non-hodgkin's lymphoma: Updated results after a median follow-up of 66.2 months from the international, randomized, phase III First-Line Indolent Trial (FIT) in 414 Patients [abstract]. Blood 2010;116:Abstract 594.

Chemotherapy followed by rituximab

Salles GA, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. The Lancet 2011;377:42-51.

DIAGNOSIS

ESSENTIAL:

- Hematopathology review of all slides with at least one paraffin block representative of the tumor. Rebiopsy if consult material is nondiagnostic.
- An FNA or core needle biopsy alone is not generally suitable for the initial diagnosis of lymphoma. In certain, circumstances, when a lymph node is not easily accessible for excisional or incisional biopsy, a combination of core biopsy and FNA biopsies in conjunction with appropriate ancillary techniques for the differential diagnosis (immunohistochemistry, flow cytometry, PCR for IgH and TCR gene rearrangements, and FISH for major translocations) may be sufficient for diagnosis.
- Adequate immunophenotyping to establish diagnosis and GCB versus non-GCB origin
 - IHC panel: CD20, CD3, CD5, CD10, CD45, BCL2, BCL6, Ki-67, IRF4/MUM1
 - or
 - Cell surface marker analysis by flow cytometry: kappa/lambda, CD45, CD3, CD5, CD19, CD10, CD20

USEFUL UNDER CERTAIN CIRCUMSTANCES:

- Additional immunohistochemical studies to establish LYMPHOMA SUBTYPE
 - IHC panel: Cyclin D1, kappa/lambda, CD30,CD138, EBER-ISH,ALK,HHV8
- Molecular analysis to detect: antigen receptor gene rearrangements; CCND1, BCL2, BCL6, MYC^e rearrangements by either FISH or IHC
- Cytogenetics or FISH: t(14;18);^e t(3;v); t(8;14)

SUBTYPES

- Subtypes included:
 - DLBCL, NOS
 - DLBCL coexistent with follicular lymphoma of any grade
 - DLBCL coexistent with gastric MALT lymphoma
 - DLBCL coexistent with nongastric MALT lymphoma
 - Follicular Lymphoma grade 3
 - Intravascular large B-cell lymphoma
 - DLBCL associated with chronic inflammation
 - ALK positive DLBCL
 - EBV positive DLBCL of the elderly
 - T-cell/histiocyte rich large B-cell lymphoma
- Subtypes *not* included:
 - Primary cutaneous B-cell lymphoma
 - Primary DLBCL of the CNS

See
Workup
(P10)

WORKUP


ESSENTIAL:


- **Physical exam: attention to node-bearing areas, including Waldeyer's ring, and to size of liver and spleen.**
- **Performance status**
- **B symptoms**
- **CBC, differential, platelets**
- **LDH**
- **Comprehensive metabolic panel**
- **Uric acid**
- **Chest/abdominal/pelvic CT with contrast of diagnostic quality**
- **Adequate bone marrow biopsy (>1.6 cm) ± aspirate**
- **Calculation of International Prognostic Index (IPI)**
- **Hepatitis B testing**
- **MUGA scan/echocardiogram if anthracycline or anthracenedione- based regimen is indicated**
- **PET-CT scan(optional)**
- **Pregnancy testing in women of child-bearing age**
- **Beta-2-microglobulin**


USEFUL IN SELECTED CASES:

- **Neck CT, Head CT, or MRI**
- **Discussion of fertility issues and sperm banking**
- **HIV**
- **Lumbar puncture, if paranasal sinus, testicular, epidural, bone marrow with large cell lymphoma, HIV lymphoma, or \geq 2 extranodal sites and elevated LDH**

See InductionTherapy
(P11)








RELAPSE/
REFRACTORY

ADDITIONAL
THERAPY

RESPONSE #2

CONSOLIDATION/
ADDITIONAL THERAPY

RELAPSE #2
OR GREATER



INTERNATIONAL PROGNOSTIC INDEX**ALL PATIENTS:**

- Age > 60 years
- Serum LDH > normal
- Performance status 2-4
- Stage III or IV
- Extranodal involvement > 1 site

INTERNATIONAL INDEX, ALL PATIENTS:

Low	0 or 1
Low intermediate	2
High intermediate	3
High	4 or 5

AGE-ADJUSTED INTERNATIONAL PROGNOSTIC INDEX**PATIENTS \leq 60YEARS**

- Stage III or IV
- Serum LDH > normal
- Performance status 2-4

INTERNATIONAL INDEX, PATIENTS \leq 60 YEARS

• Low	0
• Low/intermediate	1
• High/intermediate	2
• Hight	3



			NCCN-IPI^b	
Age, years			<u>Risk group</u>	
>40 to ≤60	1		• Low	0–1
>60 to <75	2		• Low-intermediate	2–3
≥75	3		• High-intermediate	4–5
LDH, normalized			• High	≥6
>1 to ≤3	1			
>3	2			
Ann Arbor stage III-IV	1			
Extranodal disease*	1	*Disease in bone marrow, CNS, liver/GI tract, or lung.		
Performance status ≥2	1			

^aThe International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-hodgkin's lymphoma. N Engl J Med 1993; 329:987-994.

^bThis research was originally published in *Blood*. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. *Blood* 2014;123:837-842. © the American Society of Hematology



LUGANO RESPONSE CRITERIA FOR NON-HODGKIN'S LYMPHOMA

PET should be done with contrast-enhanced diagnostic CT and can be done simultaneously or at separate procedures.

Response	Site	PET-CT (Metabolic response)	CT (Radiologic response) ^d
Complete response	Lymph nodes and extralymphatic sites	Score 1, 2, or 3 ^a with or without a residual mass on 5 point scale (5-PS) ^{b,c}	All of the following: Target nodes/nodal masses must regress to ≤ 1.5 cm in longest transverse diameter of a lesion (LDi) No extralymphatic sites of disease
	Non-measured lesion	Not applicable	Absent
	Organ enlargement	Not applicable	Regress to normal
	New Lesions	None	None
	Bone Marrow	No evidence of FDG-avid disease in marrow	Normal by morphology; if indeterminate, and flow cytometry IHC negative
Partial response	Lymph nodes and extralymphatic sites	Score 4 or 5 ^b with reduced uptake compared with baseline. No new or progressive lesions. At interim these findings suggest responding disease. At end of treatment these findings may indicate residual disease.	All of the following: $\geq 50\%$ decrease in SPD of up to 6 target measurable nodes and extranodal sites When a lesion is too small to measure on CT, assign 5mm x 5mm as the default value. When no longer visible, 0x0 mm For a node >5mm x 5mm, but smaller than normal, use actual measurement for calculation
	Non-measured lesion	Not applicable	Absent/normal, regressed, but no increase
	Organ enlargement	Not applicable	Spleen must have regressed by >50% in length beyond normal
	New Lesions	None	None
	Bone Marrow	Residual uptake higher than uptake in normal marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed). If there are persistent focal changes in the marrow in the context of a nodal response, consider further evaluation with biopsy, or an interval scan.	Not applicable

Reprinted with permission. © 2014 American Society of Clinical Oncology. All rights reserved. Cheson B, Fisher R, Barrington S, et al. Recommendations for Initial Evaluation, Staging and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma – the Lugano Classification. J Clin Oncol 2014;32:3059-3067.



LUGANO RESPONSE CRITERIA FOR NON-HODGKIN'S LYMPHOMA

PET should be done with contrast-enhanced diagnostic CT and can be done simultaneously or at separate procedures.

Response	Site	PET-CT (Metabolic response)	CT (Radiologic response) ^d
No response or stable disease	Target nodes/nodal masses, extranodal lesions	Score 4 or 5 ^b with no significant change in FDG uptake from baseline at interim or end of treatment. No new or progressive lesions	<50% decrease from baseline in SPD of up to 6 dominant, measurable nodes and extranodal sites; no criteria for progressive disease are met
	Non-measured lesion	Not applicable	No increase consistent with progression
	Organ enlargement	Not applicable	No increase consistent with progression
	New Lesions	None	None
	Bone Marrow	No change from baseline	Not applicable
Progressive disease	Individual target nodes/nodal masses Extranodal lesions	Score 4 or 5 ^b with an increase in intensity of uptake from baseline and/or New FDG-avid foci consistent with lymphoma at interim or end-of-treatment assessment ^e	Requires at least one of the following PPD progression: An individual node/lesion must be abnormal with: LDI >1.5 cm and Increase by ≥50% from PPD nadir and An increase in LDI or SDI from nadir 0.5 cm for lesions ≤2 cm 1.0 cm for lesions >2 cm In the setting of splenomegaly, the splenic length must increase by >50% of the extent of its prior increase beyond baseline. If no prior splenomegaly, must increase by at least 2 cm from baseline New or recurrent splenomegaly
	Non-measured lesion	None	New or clear progression of preexisting nonmeasured lesions
	New Lesions	New FDG-avid foci consistent with lymphoma rather than another etiology (eg, infection, inflammation). If uncertain regarding etiology of new lesions, biopsy or interval scan may be considered ^e	Regrowth of previously resolved lesions A new node >1.5 cm in any axis A new extranodal site >1.0 cm in any axis; if <1.0 cm in any axis, its presence must be unequivocal and must be attributable to lymphoma Assessable disease of any size unequivocally attributable to lymphoma
	Bone Marrow	New or recurrent FDG-avid foci	New or recurrent involvement

Reprinted with permission. © 2014 American Society of Clinical Oncology. All rights reserved. Cheson B, Fisher R, Barrington S, et al. Recommendations for Initial Evaluation, Staging and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma – the Lugano Classification. J Clin Oncol 2014;32:3059-3067.

PET 5-POINT SCALE (DEAUVILLE CRITERIA)

Score	PET/CT scan result
1	No uptake
2	Uptake \leq mediastinum
3	Uptake $>$ mediastinum but \leq liver
4	Uptake moderately higher than liver
5	Uptake markedly higher than liver and/or new lesions
X	New areas of uptake unlikely to be related to lymphoma



PRINCIPLES OF RADIATION THERAPY

General Dose Guidelines:

- Localized CLL/SLL: 24–30 Gy
- Follicular lymphoma: 24–30 Gy
- Marginal zone lymphoma:
 - Gastric: 30 Gy
 - Other extranodal sites: 24–30 Gy
 - Nodal MZL: 24–30 Gy
- Early-stage mantle cell lymphoma: 30–36 Gy
- Palliation/local control of SLL, FL, MZL, MCL: 2 Gy x 2 which may be repeated as needed

- DLBCL or PTCL
 - Consolidation after chemotherapy CR: 30–36 Gy
 - Complimentary after PR: 40–50 Gy
 - RT as primary treatment for refractory or non-candidates for chemotherapy: 40–55 Gy
 - In combination with stem cell transplantation: 20–36 Gy, depending on sites of disease and prior RT exposure
- NK-T cell lymphoma
 - RT as primary treatment 50–65 Gy
 - RT in combined modality therapy 45–60 Gy
- Primary cutaneous anaplastic large cell lymphoma: 30–36 Gy
- Primary cutaneous follicle center or marginal zone lymphoma: 24–30 Gy



SUGGESTED TREATMENT REGIMENS

(in alphabetical order) ◆ **ESHAP**

◆ **R-CHOP**

Rituximab 375mg/m² IV on day 1
 Cyclophosphamide 750 mg/m² IV on day 1
 Doxorubicin 50 mg/m² IV on day 1
 Vincristine 1.4 mg/m² IV on day 1 (maximum 2mg)
 Prednisone 60 mg/m² PO on day 1-5

Cycle every 21 days for 6-8 cycles

◆ **R-mini CHOP**

Rituximab 375mg/m² IV on day 1
 Cyclophosphamide 400 mg/m² IV on day 1
 Doxorubicin 25 mg/m² IV on day 1
 Vincristine 1 mg IV on day 1
 Prednisone 40 mg/m² PO on day 1-5

Cycle every 21 days for 6-8 cycles

◆ **CHOP**

Cyclophosphamide 750 mg/m² IV on day 1
 Doxorubicin 50 mg/m² IV on day 1
 Vincristine 1.4 mg/m² IV on day 1 (maximum 2mg)
 Prednisone 60 mg/m² PO on day 1-5

Cycle every 21 days for 6-8 cycles

◆ **CVP**

Cyclophosphamide 400 mg/m² IV on day 1-5
 (or 800 mg/m² IV on day 1-)
 Vincristine 1.4 mg/m² IV on day (maximum 2mg)
 Prednisone 60 mg/m² PO on day 1-5

Cycle every 21 days for 6-8 cycles

◆ **R-EPOCH**

Rituximab 375mg/m² IV on day 1
 Etoposide 50 mg/m² IV on day 1-4

Etoposide 40 mg/m² IV on day 1-4
 Methylprednisolone 500 mg/m² IV on day 1-4
 Cisplatin 25 mg/m² IV on day 1-4
 Cytarabine 2000 mg/m² IV on day 5 after completion of
 Cisplatin and Etoposide

Cycle every 21 days for 6-8 cycles

◆ **DHAP**

Cisplatin 100 mg/m² IV over 24 hours on day 1
 Cytarabine 2000 mg/m² IV over 3 hours every 12 hours for
 2 doses on day 2 after completion of
 Cisplatin infusion

Dexamethasone 40 mg/m² PO or IV on day 1-4

Cycle every 21 days for 6-8 cycles

◆ **Hyper-CVAD/MTX-Ara-C**

Cyclophosphamide 300 mg/m² IV every 12 hours for 6 doses on day
 1-3

Mesna 600 mg/m² on day 1-3 to start 1 hour before
 Cyclophosphamide until 12 hours after
 completion of Cyclophosphamide

Vincristine 2 mg/m² IV on day 4 and 11
 Doxorubicin 50 mg/m² IV over 24 hours on day 4
 Dexamethasone 40 mg/m² PO or IV on day 1-4 and day 11-14
 Administer every 3-4 weeks on cycles 1,3,5, and 7

Methotrexate 200 mg/m² IV over 2 hours followed by 800
 mg/m² over 22 hours on day 1

SUGGESTED TREATMENT REGIMENS

First-line Therapy

CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)+ rituximab with RT

Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-hodgkin's lymphoma. *N Engl J Med* 1998;339:21-26

Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-hodgkin's lymphoma: Eastern Cooperative Oncology Group Study 1484. *J Clin Oncol* 2004;22:3032-3038

Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014. *J Clin Oncol* 2008;26:2258-2263

CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + rituximab

Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. *Blood* 2010;116:2040-2045

Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol* 2005;23:4117-4126

Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. *Lancet Oncol* 2006;7:379-391

Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). *Lancet Oncol* 2008;9:105-116

Dose-dense CHOP 14 + rituximab

Blayney DW, LeBlanc ML, Grogan T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). *J Clin Oncol* 2003;21:2466-2473

randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma [abstract]. *J Clin Oncol* 2011;29: Abstract 8000

References

Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide doxorubicin) + rituximab

Purroy N, Lopez A, Vallespi T, Gironella M, Bergua J, Sancho JM. Dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor risk large B-cell lymphoma. A phase 2 study conducted by the Spanish PETHEMA Group [Abstract]. *Blood* 2009;114:Abstract 2701

Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. *J Clin Oncol* 2008;26:2717-2724

First-line Therapy for patients with poor ventricular left function

CDOP (cyclophosphamide, liposomal doxorubicin, vincristine and prednisone) + Rituximab

Martino R, Perea G, Caballero MD, et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: Results from a prospective phase II study. *Haematologica* 2002;87:822-827.

Zaja F, Tomadini V, Zaccaria A, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. *Leuk Lymphoma* 2006;47:2174-2180

CNOP (cyclophosphamide, mitoxantrone, vincristine, prednisone) + rituximab

Bessell EM, Burton A, Haynes AP, et al. A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma. *Ann Oncol* 2003;14:258-267.

Bezwooda W, Rastogi RB, Erazo Valla A, et al. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. *Novantrone International Study Group. Eur J Cancer* 1995;31A:903-911.

Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. *J Clin Oncol* 1995;13:2530-2539.

RCEOP (rituximab, cyclophosphamide, etoposide, vincristine, prednisone)

Moccia A, Schaff K, Hoskins P, et al. R-CHOP with etoposide substituted for doxorubicin(RCEOP): Excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines [abstract]. *Blood* 2009;114:Abstract 408

First-line consolidation

Stiff PJ, Unger JM, Cook J, et al. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP {+/-} R for eight cycles to CHOP {+/-} R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL) [abstract]. *J Clin Oncol* 2011;29: Abstract 8001



Ann Arbor Stage

StageI	Involvement of a single lymphatic site(i.e. nodal region,Waldeyer's ring,thymus or spleen)(I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement(IE)(rare in Hodgkin lymphoma)
StageII	Involvement of two or more lymph node regions on the same side of the diaphragm(II); or localized involvement of a single extralymphatic organ or site in association with or without involvement of other lymph node regions on the same side of the diaphragm(IIIE).The number of regions involved may be indicated by a subscript,as in,for example.II.
StageIII	Involvement of lymph node regions on both sides of the diaphragm(III),which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).Splenic involvement is designated by the letter S.
StageIV	Diffuse or disseminated involvement of one or more extralymphatic organs,with or without associated lymph node involvement;or isolated extralymphatic organs involvement in the absence of adjacent regional lymph node involvement,but in conjunction with disease in distant site(s).Stage IV includes any involvement of the liver or bone marrow,lungs(others than by direct extension from another site),or cerebrospinal fluid.

Modifiers for Group:

E Extranodal

S Spleen

- ▶ Complementary after PR: 40-50 Gy
- ▶ RT as primary treatment for refractory or non-candidates for chemotherapy: 40-55 Gy
- ▶ In combination with stem cell transplantation: 20-36 Gy, depending on sites of disease and prior RT exposure
- NK-T cell lymphoma
 - ▶ RT as primary treatment 50-65 Gy
 - ▶ RT in combined modality therapy 45-60 Gy
- Primary cutaneous anaplastic large cell lymphoma: 30-36 Gy
- Primary cutaneous follicle center or marginal zone lymphoma: 24-30 Gy